Indonesia Grants Marketing Approval for Mabwell’s Adalimumab Biosimilar In a move that could broaden access to biologic therapies for autoimmune conditions, Mabwell, a Shanghai-based biopharmaceutical company, announced that its Adalimumab Injection 9MW0113 (marketed as JUNMAIKANG in China) has received marketing approval in Indonesia. The approval marks a key milestone for Mabwell’s global expansion strategy and…